Journal of the College of Physicians and Surgeons Pakistan
ISSN: 1022-386X (PRINT)
ISSN: 1681-7168 (ONLINE)
Affiliations
doi: 10.29271/jcpsp.2025.12.1521ABSTRACT
Objective: To compare distal transradial access (dTRA) via the anatomical snuffbox as an alternative to conventional transradial access (TRA) for coronary angiography and angioplasty in terms of clinical outcomes and feasibility.
Study Design: An observational study.
Place and Duration of the Study: Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan, from August 2022 to January 2023.
Methodology: This study analysed medical records involving 100 participants, through a convenience sampling, who underwent angio- graphy, with or without angioplasty, during the years 2022-2023. The participants were divided into two groups: Fifty patients were randomly selected for the conventional TRA group (Group T) and 50 for the dTRA group (Group D). Both groups were compared based on procedure type and the target vessel for angioplasty to minimise bias. Stratification analysis was performed using the independent t-test or Mann-Whitney U test (two-tailed) for quantitative data, and the Chi-square or Fisher's exact test for qualitative data to compare the groups based on their clinical and demographic profiles, procedural characteristics, and follow-up data, including post-procedural complications.
Results: The mean age of participants was comparable between Group D (58.6 ± 9.26 years) and Group T (57.8 ± 9.80 years). Procedural parameters, including median procedure time (Group D: 25 minutes; Group T: 25 minutes) and median fluoroscopy time (Group D: 6.40 minutes; Group T: 4.90 minutes), showed no significant differences (p >0.05). Group D had a higher proportion of procedures for acute coronary syndrome (ACS) (56.0% vs. 34.0%; p = 0.044); however, no differences were observed for other indications. Haematoma incidence (Group D 2.0% vs. Group T 12%; p = 0.004) and haemostasis time (Group D vs. Group T) were significantly lower in Group D.
Conclusion: dTRA demonstrated comparable procedural efficiency to conventional TRA while offering significant advantages in safety and post-procedural outcomes. The faster haemostasis and reduced incidence of complications, particularly haematoma formation, suggest that dTRA may provide a safer vascular access alternative, minimising patient discomfort and enhancing recovery.
Key Words: Transradial access, Distal radial artery access, Snuffbox, Coronary angiography, Coronary angioplasty.
INTRODUCTION
Since its inception, percutaneous cardiac catheterisation has evolved significantly, with the introduction of the Seldinger technique representing a major advancement in minimally invasive vascular access.1,2 While the femoral artery was historically preferred for coronary angiography, its association with bleeding and vascular complications, particularly in anti- coagulated patients, has shifted focus toward transradial access (TRA), which offers greater safety, faster recovery, and improved patient comfort.3-6
A newer technique, distal transradial access (dTRA), targets the radial artery within the anatomical snuffbox—a depression bordered by tendons and bones when the thumb is extended. This approach preserves collateral circulation, reduces hand ischaemia risk, and allows faster haemostasis due to the smaller arterial calibre.7-9 Despite these advantages, evidence supporting the routine use of dTRA remains limited.
Most of the studies using the dTRA approach have been con- ducted on the European population. There is a paucity of data on dTRA access and its outcomes from the South Asian population. This study aimed to evaluate the feasibility, safety, and clinical outcomes of dTRA access compared with conventional TRA for coronary procedures in a South Asian population, addressing the current lack of regional data on this technique.
METHODOLOGY
This single-centre, prospective observational study was con- ducted after obtaining ethical approval from the Ethical Review Committee of the Aga Khan University Hospital, Karachi, Pakistan, from August 2022 to January 2023. A total of 100 patients who underwent coronary angiography (50 via dTRA and 50 via conventional TRA), with or without angioplasty/ percutaneous coronary intervention (PCI), were included using a convenience sampling method. Both groups were compared for procedure type and target vessel for angioplasty to minimise bias, as these factors can independently influence procedure and fluoroscopy times.1,3 Patients aged >18 years presenting with typical angina or acute coronary syndrome were included, while those who refused consent or had incomplete data were excluded. A convenience sample of 100 patients was selected over six months due to the limited availability of eligible cases and the absence of established local baseline data. This sample size was deemed sufficient to explore feasibility and generate preliminary outcome trends.
Patients were divided into two groups based on the access site: conventional TRA (Group T) and dTRA (Group D). Data were collected from medical records using a pre-designed form and included data such as age, gender, comorbidities, presentation mode, procedural specifics, and follow-up outcomes. Acute coronary syndrome (ACS) and its subclasses were defined based on ACC/AHA guidelines.10 Similarly, the severity of angina was classified based on the Canadian Cardiac Society (CCS).11 Informed consent was obtained, and follow-ups were conduc- ted two days post-procedure. During the procedure, data on in-hospital haemostasis and complications were recorded. The collected data were reviewed and analysed using certified standard software. Demographic, clinical, and procedural data were extracted from medical records using standardised forms. ACS classification followed ACC/AHA guidelines; angina severity was graded as per CCS criteria. Follow-up assessments were conducted for 2 days and 1 week following the procedure.
Vascular access was obtained via either the conventional TRA approach or dTRA at the anatomical snuffbox, with right-sided access preferred when feasible. Arterial puncture was initially performed using the manual technique, with ultrasound guidance utilised in cases of difficulty. Following successful puncture, a 5F or 6F GlideSlender sheath was introduced after local anaesthaesia with 2% lidocaine infiltration. A standardised spasmolytic cocktail consisting of nitroglycerin and heparin was administered intra-arterially. Additional heparin was administered during PCI to maintain an adequate activated clotting time (ACT). Dual antiplatelet therapy was prescribed for all patients undergoing PCI, in accordance with institutional practice. Haemostasis was achieved using a modified compression dressing for dTRA cases (60 minutes following diagnostic angiography and 90 minutes following PCI), whereas a TR Band was applied for conventional TRA cases (180 minutes following diagnostic angiography and 240 minutes following PCI).
Outcome assessment focused on both primary and secondary endpoints. Primary endpoints included procedural success, which was defined as successful sheath insertion and completion of the intervention, haemostasis time, and access-site complications such as haematoma, radial artery occlusion, and patient-reported pain. Secondary endpoints involved evaluation of radial artery patency using the Allen’s or Barbeau test, and assessment of post-procedural hand function to ensure preserved limb functionality.
Data analysis was conducted using R Studio (version 4.1.2, Boston, USA). Normality assumptions for numerical variables such as age, height, and weight were assessed using the Shapiro-Wilk test. Descriptive statistics were reported as mean ± SD or median (IQR), for normally distributed or skewed data, respectively. Categorical data such as gender, hypertension, diabetes mellitus, and smoking status were analysed in terms of frequencies (percentages). Stratification analysis based on Group D and T was performed, and statistical associations were determined using the independent t-test or Mann-Whitney U test (two-tailed) for quantitative data, and the Chi-square or Fisher's exact test for qualitative data. A p-value of <0.05 was considered statistically significant.
RESULTS
The study enrolled a total of 100 participants, with 50 indivi- duals assigned to Group D and 50 to Group T. As shown in Table I, the demographic characteristics, including age, height, and gender distribution, were comparable between the groups, with no statistically significant differences observed (p >0.05). However, patients in Group T had more weight compared to Group D (p = 0.029). The mean age of participants was 58.6 ± 9.26 years in Group D, and 57.8 ± 9.80 years in Group T, with an overall mean age of 58.2 ± 9.50 years.
Regarding comorbid conditions, Group T had more patients with hypertension (p = 0.03) and dyslipidaemia (p <0.001) compared to Group D, while the rest of the conditions were comparable between both groups.
Analysis of procedure indications revealed statistically significant differences between the groups. Group D had a higher proportion of cases attributed to ACS, accounting for 28 procedures (56.0%), compared to 17 procedures (34.0%) in Group T (p = 0.044). However, there were no significant differences in other indications, such as Elective or ACS, between the two groups (p >0.05).
In terms of procedural parameters (Table II), such as procedure time and fluoroscopy time, no significant disparities were observed between the groups (p > 0.05). The median procedure time for both groups was 25 minutes. Group D had a median time of 25 minutes (Q1, Q3: 15,43.8), and Group T had a median of 25 minutes (Q1, Q3: 15, 13.8; p = 0.228), indicating similar intervention duration across the groups. Similarly, the median fluoroscopy time, a crucial metric for assessing radiation exposure during procedures, showed no significant difference between Group D (median time of 6.40 minutes [Q1, Q3: 3.60, 13.1]) and Group T (median time of 4.90 minutes [Q1, Q3, 3.65, 6.50]; p = 0.132).
Table I: Comparative clinical characteristics of the patients.
|
Variables |
Group D (n = 50) |
Group T (n = 50) |
Overall (n = 100) |
p-values |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Age |
- | - | - |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Mean ± SDb |
58.6 ± 9.26 |
57.8 ± 9.80 |
58.2 ± 9.50 |
0.691 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Height (cm) |
- | - | - |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Medianc [Q1, Q3] |
165 [160, 173] |
167 [152, 171] |
166 [156, 172] |
0.656 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Weight (kg) |
- | - | - |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Mean ± SDb |
74.4 ± 13.0 |
79.4 ± 9.28 |
76.9 ± 11.5 |
0.029* |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Gender |
- | - | - |
0.494 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Male |
39 (78.0%) |
35 (70.0%) |
74 (74.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Female |
11 (22.0%) |
15 (30.0%) |
26 (26.0%) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension |
- | - | - |
0.030* |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
34 (68.0%) |
44 (88.0%) |
78 (78.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Diabetes mellitus |
- | - | - |
0.416 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
18 (36.0%) |
23 (46.0%) |
41 (41.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dyslipidaemia |
- | - | - |
<0.001* |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
9 (18.0%) |
35 (70.0%) |
44 (44.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Peripheral arterial disease |
50 (100%) |
50 (100%) |
100 (100%) |
>0.900 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Smoker |
- | - | - |
0.217 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
11 (22.0%) |
19 (38.0%) |
30 (30.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CKD |
- | - | - |
0.712 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
5 (10.0%) |
3 (6.0%) |
8 (8.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
COPD |
- | - | - |
>0.900 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
3 (6.0%) |
2 (4.0%) |
5 (5.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Prior CABG |
- | - | - |
>0.900 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
0 (0%) |
1 (2.0%) |
1 (1.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Prior stroke |
- | - | - |
>0.900 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
1 (2.0%) |
1 (2.0%) |
2 (2.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Prior PCI |
- | - | - |
>0.900 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
6 (%) |
8 (%) |
76 (76.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
History of atrial fibrillation |
- | - | - |
>0.900 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Yes |
0 (0%) |
1 (2.0%) |
1 (1.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Indication for procedure |
- | - | - |
0.044* |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ACS |
28 (56.0%) |
17 (34.0%) |
45 (45.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Elective |
22 (44.0%) |
33 (66.0%) |
55 (55.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ACS |
- | - | - |
0.115 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
USAP |
21 (42.0%) |
8 (16.0%) |
29 (29.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NSTE-ACS |
7 (14.0%) |
9 (18.0%) |
16 (16.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Elective (CCS class of angina) |
- | - | - |
0.694 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CCS2 |
10 (20.0%) |
12 (24.0%) |
22 (22.0%) |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CCS3 |
12 (24.0%) |
21 (42.0%) |
33 (33.0%) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
*Statistically significant results, aChi-square or Fisher's exact, bIndependent t-test cMann-Whitney U test (two-tailed). CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; CABG: Coronary artery bypass grafting; PCI: Percutaneous coronary intervention; ACS: Acute coronary syndrome; USAP: Unstable anginal pain; NSTE-ACS: Non-ST elevation-acute coronary syndrome; CCS: Canadian Society of Cardiology.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Post-procedural complications (Table II) were also assessed during hospitalisation, with particular attention to haematoma formation. There was no difference in the incidence of haemostasis between both groups; however, the time to achieve haemostasis differed significantly, with Group D achieving haemostasis faster than Group T (Group D: 135 ± 19.40 mins vs. Group T: 196.8 ± 19.31 mins, p-value <0.001). Similarly, a statistically significant difference was observed in the incidence of haematoma between Group D and Group T. Specifically, 1 case (2.0%) in Group D experienced post-procedural haematoma, compared to 6 cases (12.0%) in Group T (p = 0.004), indicating a higher risk of haematoma formation in Group T. All patients were discharged on the same day, with a follow-up period of 2 days. Moreover, after one week of the procedure, all patients were assessed. Based on clinical examination, there were no complaints of access site pain and/or hand clumsiness, and no radial artery occlusion was assessed by clinical tests in both groups.
DISCUSSION
This study demonstrates that dTRA is a safer and more effective technique than conventional TRA in a South Asian population, offering notable advantages in haemostasis and post-procedural outcomes. While demographic characteristics were largely comparable between groups, Group T had a higher prevalence of overweight patients and cardiovascular risk factors, including hypertension and dyslipidaemia, which may have contributed to the observed differences in complication rates. Previous studies have associated elevated body mass index with a reduced bleeding risk in TRA compared to femoral access; however, findings from this study suggest that dTRA may further mitigate vascular complications, particularly in higher-risk patients.12-15 The dTRA approach, performed via the anatomical snuffbox, combines procedural efficiency with ergonomic benefits for both the operator and the patient. Contrary to concerns regarding technical difficulty,16-18 this study found no significant differences in procedural or fluoroscopy time between dTRA and TRA (p >0.05), even in ACS cases, which were more prevalent in the dTRA group. This challenges prior assumptions about radial spasm and tortuosity, limiting the utility of dTRA in urgent settings.14-16 Notably, dTRA was associated with significantly faster haemostasis and a lower incidence of haematoma (p = 0.004), likely due to the smaller vessel size and superficial puncture site. At one-week follow-up, neither group exhibited radial artery occlusion, hand dysfunction, or chronic pain, reinforcing the safety profile of dTRA.
The clinical implications of this research are remarkable, as dTRA enables same-day discharge, preserves proximal access options, and reduces hand congestion risks, consistent with findings from other studies.12,13,16,19,20 However, limitations of this study include single-centre design, moderate sample size, and short follow-up period. Larger multicentre studies with extended observation are recommended to validate these findings and assess long-term vascular out- comes. Future research should also explore the applicability of dTRA in diverse populations and complex interventions. Despite these limitations, these results support dTRA as a promising refinement of transradial techniques, particularly in regions with high cardiovascular risk burdens.
CONCLUSION
This study demonstrated that dTRA access is a safe, feasible, and advantageous alternative to conventional transradial techniques for coronary procedures. These findings indicated that the dTRA offers clinically significant benefits, including faster haemostasis and reduced haematoma formation, while maintaining comparable procedural efficiency.
ETHICAL APPROVAL:
Ethical approval was obtained from the Institutional Review Board of the Aga Khan University, Karachi, Pakistan (Approval No. 2020-3360-11382).
PATIENTS’ CONSENT:
Informed consent was obtained from all the patients included in the study.
COMPETING INTEREST:
The authors declared no conflict of interest.
AUTHORS’ CONTRIBUTION:
AN: Interpretation of results and manuscript writing.
GA: Data collection, analysis, preparation of tables, and interpretation of results.
IU: Study design and data collection.
AF, TM: Data analysis, critical review, and editing corrections.
MNR: Conception and design of the study, contribution to data acquisition, interpretation, and proofreading.
All authors approved the final version of the manuscript to be published.
REFERENCES